Department of Cardiothoracic Surgery, University Hospital Regensburg, Regensburg, Germany.
Department of Anesthesiology, University Hospital Regensburg, Regensburg, Germany.
Artif Organs. 2022 Aug;46(8):1669-1681. doi: 10.1111/aor.14218. Epub 2022 Mar 3.
Patients with severe coronavirus disease-19 (COVID-19)-associated acute respiratory distress on venovenous extracorporeal lung support (V-V ECLS) showed a high incidence of vascular as well as ECLS-related thrombotic complications. The latter may influence the outcome of the patients.
This is a retrospective monocentric study on prospectively collected data of technical complications including 69 adult COVID-19 patients on V-V ECLS (ECLS Registry, March 2020 until April 2021) without and with system exchanges. Alterations in ECLS-specific data, hemolysis, coagulation, and hemostasis parameters were analyzed.
Every second COVID-19 patient on V-V ECLS developed technical complications. Optimized ECLS management at our ECLS center reduced cases of acute clot formation (pump head thrombosis, acute oxygenator thrombosis) (17%), and allowed early identification of progressive clotting processes (worsened gas transfer, coagulation disorder) (14%, 54%) with a significant overhang of hyperfibrinolysis (37%). Although COVID-19 disease and technical complications caused the prolonged length of stay at the intensive care unit and ECLS support times, the proportion of successful weaning and survival rates were comparable with patients without system exchange.
The survival of ECLS patients with COVID-19 was independent of the requirement for system exchange due to technical-induced coagulation disorders. Close monitoring for circuit clotting is mandatory in COVID-19 patients and is one prerequisite for successful organ support in these difficult patients.
接受静脉-静脉体外膜肺氧合(V-V ECMO)治疗的严重 2019 冠状病毒病(COVID-19)相关急性呼吸窘迫综合征患者血管和 ECMO 相关血栓形成并发症发生率较高。后者可能影响患者的预后。
这是一项回顾性单中心研究,对 2020 年 3 月至 2021 年 4 月期间接受 V-V ECMO 治疗的 69 例成年 COVID-19 患者(ECLS 登记处)的前瞻性收集数据进行分析,其中包括无系统更换和有系统更换的患者。分析 ECMO 特定数据、溶血、凝血和止血参数的变化。
每 2 例接受 V-V ECMO 治疗的 COVID-19 患者中就有 1 例发生技术并发症。我们的 ECMO 中心优化 ECMO 管理,降低了急性血栓形成(泵头血栓形成、急性氧合器血栓形成)的发生率(17%),并早期识别出进行性凝血过程(气体交换恶化、凝血障碍)(14%,54%),明显伴有过度纤溶亢进(37%)。尽管 COVID-19 疾病和技术并发症导致重症监护病房和 ECMO 支持时间延长,但成功撤机和存活率与无系统更换的患者相当。
由于技术引起的凝血障碍,COVID-19 患者 ECMO 治疗的存活率与系统更换的需求无关。COVID-19 患者必须密切监测回路凝血情况,这是成功为这些困难患者提供器官支持的前提之一。